Birch pollen allergy vaccine - Anergis

Drug Profile

Birch pollen allergy vaccine - Anergis

Alternative Names: AllerT; AllerT-Birch

Latest Information Update: 26 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Lausanne
  • Developer Anergis
  • Class Antiallergics; Peptide vaccines; Peptides; Tree pollen allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Allergic rhinoconjunctivitis

Most Recent Events

  • 26 Sep 2017 Anergis completes a phase II trial in Allergic rhinoconjunctivitis in Denmark, Finland, Germany, Lithuania, Norway, Poland, Slovakia and Sweden (NCT02943720)
  • 06 Sep 2017 Efficacy and adverse events data from a phase II trial in Allergic rhinoconjunctivitis released by Anergis
  • 03 Mar 2017 Immunogenicity data from a phase II trial in Allergic rhinoconjunctivitis presented at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAI-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top